Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 8;29(15):1945-1954.
doi: 10.1093/eurjpc/zwac089.

Impact of chronic coronary syndromes on cardiovascular hospitalization and mortality: the ESC-EORP CICD-LT registry

Mathieu Kerneis  1 , Francesco Cosentino  2 , Roberto Ferrari  3   4 , Jean-Louis Georges  5   6 , Elena Kosmachova  7 , Cécile Laroche  8 , Aldo P Maggioni  4   8 , Harald Rittger  9 , Philippe Gabriel Steg  10   11 , Justyna Maczynska  12 , Luigi Tavazzi  4 , Marco Valgimigli  13 , Chris P Gale  14 , Michel Komajda  15   16 ; CICD investigators group
Collaborators, Affiliations
Free article

Impact of chronic coronary syndromes on cardiovascular hospitalization and mortality: the ESC-EORP CICD-LT registry

Mathieu Kerneis et al. Eur J Prev Cardiol. .
Free article

Abstract

Aims: In Europe, global data on guideline adherence, geographic variations, and determinants of clinical events in patients with chronic coronary syndrome (CCS) remain suboptimal. The European Society of Cardiology (ESC) EURObservational Research Programme (EORP) Chronic Ischemic Cardiovascular Disease Long-Term (CICD-LT) registry is a prospective European registry, and was designed to describe the profile, management, and outcomes of patients with CCS across the ESC countries.

Methods and results: We aimed to investigate clinical events at 1-year follow-up from the ESC EORP CICD-LT registry.One-year outcomes of 6655 patients from the 9174 recruited in this European registry were analysed. Overall, 168 patients (2.5%) died, mostly from cardiovascular (CV) causes (n = 97, 1.5%). Northern Europe had the lowest CV mortality rate, while southern Europe had the highest (0.5 vs. 2.0%, P = 0.04). Women had a higher rate of CV mortality compared with men (2.0 vs. 1.3%, P = 0.02). During follow-up, 1606 patients (27.1%) were hospitalized at least once, predominantly for CV indications (n = 1220, 20.6%). Among the population with measured low-density lipoprotein-cholesterol level at 1 year, 1434 patients (66.5%) were above the recommended target. Age, history of atrial fibrillation, previous stroke, liver disease, chronic obstructive pulmonary disease or asthma, increased serum creatinine, and impaired left ventricular function were associated with an increased risk of CV death or hospitalization.

Conclusion: In the CICD registry, the majority of patients with CCS have uncontrolled CV-risk factors. The 1-year mortality rate is low, but these patients are frequently hospitalized for CV causes. Early identification of comorbidities may represent an opportunity for enhanced care and better outcomes.

Keywords: Chronic coronary syndromes; Cohort; Management; Outcomes.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: M.Ke. reports research grants from institut servier, federation francaise de cardiologie, and consulting fees from Bayer, Kiniksa, Sanofi, and Servier. F.C. reports personal fees from Novo Nordisk, personal fees from MSD, personal fees from Pfizer, personal fees from Mundipharma, personal fees from Eli Lilly, personal fees from Boehringer Ingelheim, personal fees from AstraZeneca, personal fees from BMS, outside the submitted work. R.F. reports personal fees from Servier International, grants and personal fees from Novartis, personal fees from Merck Serono, personal fees from Boehringer Ingelheim, personal fees from Sun Pharma, personal fees from Lupin, personal fees from Doc Generici, personal fees from Pfizer, personal fees from Spa Prodotti Antibiotici, outside the submitted work; and Director of Art Research and Science S.r.l. J.L.G., H.R., E.K., and C.L. have nothing to disclose. A.P.M. reports personal fees from Bayer, personal fees from Fresenius, personal fees from Novartis, outside the submitted work. P.G.S. reports grants and personal fees from Bayer/Janssen, grants and personal fees from Merck, grants and personal fees from Sanofi, grants and personal fees from Amarin, personal fees from Amgen, personal fees from Bristol Myers Squibb, personal fees from Boehringer Ingelheim, personal fees from Pfizer, personal fees from Novartis, personal fees from Regeneron, personal fees from Lilly, personal fees from AstraZeneca, grants and personal fees from Servier, outside the submitted work. L.T. reports personal fees from Servier, personal fees from CVie Therapeutics, outside the submitted work; M.V. reports personal fees from AstraZeneca, grants and personal fees from Terumo, personal fees from Alvimedica/CID, personal fees from Abbott Vascular, personal fees from Daiichi Sankyo, personal fees from Opsens, personal fees from Bayer, personal fees from CoreFlow, personal fees from Idorsia Pharmaceuticals Ltd, personal fees from Department Klinische Forschung, Universität Basel, personal fees from Vifor, personal fees from Bristol Myers Squib SA, personal fees from iVascular, personal fees from Medscape, outside the submitted work. C.P.G. reports non-financial support from Bayer, grants, personal fees, and non-financial support from Bristol Myers Squib, personal fees and non-financial support from Novartis, personal fees and non-financial support from AstraZeneca, personal fees from Vifor Pharma, grants from Abbot, personal fees from Daiichi Sankyo, outside the submitted work. M.Ko. reports personal fees from Novartis, Servier, MSD, Sanofi, AstraZeneca, TORRENT, Amgen, Bayer, outside the submitted work.

Comment in

Publication types